Product image of Jazeta Novum (Sitagliptin Phosphate Monohydrate) supplied by GNH India

Jazeta Novum

Active Ingredient:
Sitagliptin Phosphate Monohydrate
Origin:
EU

Jazeta Novum (Sitagliptin Phosphate Monohydrate)

Sitagliptin, the active ingredient in Jazeta Novum, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycemic control when used as part of a comprehensive diabetes treatment plan that includes diet and exercise.

GNH India supplies Jazeta Novum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Manufacturer / TM Owner

Zentiva, K.S.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Jazeta Novum, a DPP‑4 inhibitor, is used to treat disorders of glucose metabolism, primarily type 2 diabetes mellitus.

  • Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels as part of a diet‑and‑exercise regimen.
  • Type 2 diabetes mellitus (combination therapy): enhances glycemic control when added to metformin or other oral antidiabetic agents.
  • Type 2 diabetes mellitus (adjunct to lifestyle): supports maintenance of target HbA1c when diet and exercise alone are insufficient.

How It Works

  • Sitagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which results in increased circulating levels of the incretin hormones GLP‑1 and GIP. Elevated incretins enhance glucose‑dependent insulin secretion from pancreatic beta cells and suppress glucagon release from alpha cells, thereby improving post‑prandial and overall glycemic control.

Side Effects

Common Side Effects

  • Nasopharyngitis: mild inflammation of the nose and throat.
  • Headache: transient mild to moderate pain.
  • Upper respiratory tract infection: symptoms of cough and congestion.
  • Nausea: occasional stomach upset.
  • Diarrhea: loose stools that are usually self‑limiting.
  • Joint pain: arthralgia without swelling.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe hypersensitivity reactions: including rash, angioedema, or anaphylaxis.
  • Bullous pemphigoid: blistering skin disorder.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Acute renal failure: sudden decrease in kidney function.
  • Cardiovascular events: rare reports of heart failure exacerbation.

Precautions & Warnings

Before initiating therapy, consider the following precautions:

  • Renal impairment: dose adjustment may be required based on creatinine clearance.
  • Hepatic impairment: use with caution in patients with liver disease.
  • History of pancreatitis: avoid or monitor closely for recurrence.
  • Hypersensitivity: discontinue if signs of allergic reaction appear.
  • Cardiovascular disease: monitor patients with existing heart conditions.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Sitagliptin may interact with other medicines; review the following categories:

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase sitagliptin exposure.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce sitagliptin exposure.

Moderate Interactions (Monitor Closely)

  • Insulin or sulfonylureas: increased risk of hypoglycemia.
  • Diuretics: may affect glycemic control.
  • ACE inhibitors or ARBs: monitor renal function and electrolytes.

Frequently Asked Questions

Jazeta Novum contains sitagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus in adults. It is used to improve blood glucose control when combined with diet, exercise, and, when appropriate, other antidiabetic agents.

Sitagliptin blocks the enzyme dipeptidyl peptidase‑4, which results in higher levels of the incretin hormones GLP‑1 and GIP. These hormones increase insulin secretion and decrease glucagon release in a glucose‑dependent manner, helping to lower blood sugar levels.

The dosage of Jazeta Novum is determined by the prescribing healthcare professional based on the individual’s renal function, glycemic targets, and overall treatment plan. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of sitagliptin in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, sitagliptin has a lower risk of causing hypoglycemia because its glucose‑dependent mechanism requires elevated blood sugar to stimulate insulin. Unlike insulin, it is an oral agent, and unlike metformin, it does not typically cause gastrointestinal upset.

Jazeta Novum should be stored at ambient temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date.

Jazeta Novum is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew it unless specifically instructed.

Serious risks include pancreatitis, severe allergic reactions such as anaphylaxis or bullous pemphigoid, and rare cases of hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or jaundice.

Jazeta Novum is contraindicated in patients with a known hypersensitivity to sitagliptin or any of the tablet’s excipients. Caution is advised for individuals with a history of pancreatitis, severe renal impairment, or significant liver disease, and it should be avoided in these cases unless a physician determines otherwise.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin Phosphate Monohydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT